Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Core Viewpoint - Aprea Therapeutics shares are experiencing an increase following the announcement of additional preliminary data from the Phase 1 trial of APR-1051, a WEE1 kinase inhibitor [1] Group 1: Cancer Trial Data - A second unconfirmed partial response was reported in a patient with advanced endometrial cancer, showing a 50% reduction in target lesion measurements [2] - CA-125 tumor biomarker levels decreased significantly from 362 U/mL at baseline to 47 U/mL, indicating promising anti-tumor activity [2] Group 2: Trial Progress and Future Plans - Enrollment in the 220 mg dose cohort is ongoing, with plans to expand the study to include more patients with specific genetic alterations [3] - The trial aims to evaluate the safety and efficacy of APR-1051, with further updates expected in the second quarter of 2026 [3] Group 3: Analyst Consensus & Recent Actions - The stock currently carries a Buy Rating, with Aprea Therapeutics shares up 16.62% at $0.70 at the time of publication [4] - Recent analyst actions include Wedbush rating it as Outperform with a target lowered to $7.00 and HC Wainwright & Co. maintaining a Buy rating with a target lowered to $4.00 [4]